Download PDF
Osteologie 2014; 23(04): 251-261
DOI: 10.1055/s-0037-1622029
Osteoonkologie
Schattauer GmbH

Moderne Osteoprotektion in der Onkologie

Current approaches to osteoprotection in oncology
I. J. Diel
1   Schwerpunktpraxis für Gynäkologische Onkologie, Mannheim
› Author Affiliations
Further Information

Publication History

eingereicht: 23 October 2014

angenommen: 27 October 2014

Publication Date:
02 January 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Knochenmetastasen zerstören den Knochen, dadurch dass Tumorzellen über parakrine Sekretion von osteotropen Substanzen den RANK/RANKL/OPG-Signalweg aktivieren, der zu einer gesteigerten Osteoklastenaktivierung führt. Bei der subsequenten Zerstörung der Knochenmatrix werden zuvor eingelagerte Wachstumsfaktoren freigesetzt, die zu einer Steigerung der proliferativen Aktivität der Tumorzellen beitragen können (Circulus vitiosus, maligner Dialog). Antiosteolytische Substanzen hemmen die Neubildung und/ oder Aktivierung von Osteoklasten und reduzieren so das Ausmaß der skelettalen Zerstörung. Das Ziel aller Therapiemaßnahmen bei Knochenmetastasen ist die Reduktion so - genannter skelettaler Komplikationen, wie Knochenschmerz, pathologische Frakturen, spinale Kompressionssyndrome und hyperkalzämische Episoden, um die Lebensqualität der Patienten zu verbessern und deren Überlebenszeit zu verlängern. Nicht nur die Therapie kann im Rahmen einer Tumorerkrankung zu einer Osteoporose führen, auch die Grundkrankheit selbst kann durch reduzierte körperliche Aktivität, Immobilisierung, Nausea, Mangel ernährung und direkte Effekte des Tumors zu einer Reduktion der Knochenmasse führen. Als eigenständiger Risikofaktor gilt jedoch insbesondere die medikamentöse Therapie. Zahlreiche Chemotherapeutika können den Knochen direkt, auch ohne Ausschaltung der gonadalen Aktivität, schädigen. Weitaus nachhaltiger wird der Knochen durch den Hypogonadismus beeinträchtigt, der bei Patienten mit hormonempfindlichen Tumoren erwünschtes Therapieziel ist. Zur Behandlung und Prophylaxe der Osteoporose gibt es zahlreiche medikamentöse Möglichkeiten, aber mit keiner anderen Substanzklasse liegen bei der tumortherapieinduzierten (TTI) Osteoporose so gute Resultate vor wie zu den Bisphosphonaten. Zumindest gleich gute Ergebnisse erzielt man mit der Anwendung von Denosumab bei Mammakarzinompatientinnen mit Aromatasehemmer-induzierter Osteopenie und bei Männern mit Prostatakarzinom und Androgenblockade. Kaum eine Einsatzmöglichkeit von osteoprotektiven Substanzen ist in den vergangenen Jahren so kontrovers diskutiert worden wie die Option zur Vermeidung von Knochenmetastasen. Das liegt zum größten Teil an den sehr divergenten Ergebnissen der einzelnen Studien, insbesondere zum Einsatz von Clodronat oder Zoledronat adjuvant. Nach einer kürzlich erschienenen Metaanalyse verbessern Bisphosphonate signifikant das knochenmetastasenfreie und das Gesamtüberleben – und das trotz Unterschieden in Applikationsweise, Patientenkollektiven und Einschlusskriterien der jeweiligen Studien. Es gibt also berechtigte Hinweise, diese Indikation weiter zu untersuchen, um herauszufinden wer von einem adjuvanten Einsatz profitiert und wer nicht. Nach derzeitigem Wissensstand sind es Patientinnen mit hohem Rezidivrisiko, aktiviertem Knochenstoffwechsel (Östrogen - depletion, postmenopausal) und/oder Tumorzellen im Knochenmark.

Summary

Bone metastases destroy the bone through paracrine secretion of osteotropic substances by tumour cells. Those substances lead to a higher activity of osteoclasts by influencing the RANK/RANKL/OPG signal path. The subsequent destruction of the osseous matrix releases growth factors which were previously stored within the bone and which can increase the proliferating activity of the tumorous cells (vicious cycle). Antiosteolytical drugs reduce the fusion and/or activation of osteoclasts and lower the degree of skeletal damage. All measures of therapy against bone metastases aim at the reduction of so called skeletal complications (events). The most important thing that is ought to be fought is bone pain, followed by pathological fractures, spinal cord compression and hypercalcemic episodes. The avoidance of such complications does not merely lead to an improvement in quality of life but can also prolong the survival time by lowering the level of immobility and decreasing the hospitalization rate in some individuals. It is by no means only the therapy that can lead to osteoporosis in patients with a tumour disease, it can also be caused by the disease itself. A lack of physical activity, immobilization, nausea, malnutrition and direct influences of the tumour can all contribute to a reduction of bone mass. But particularly the medication has to be seen as a separate and distinct risk factor. A wide range of chemotherapeutics socan harm the bone directly, even without neutralizing hormonal activity. Also the impairing effect of hypogonadism on the bone can be vast – even though hypogonadism is one of the specific goals in the treatment of patients with hormone sensitive tumours. The therapy and prophylaxis of primary and secondary osteoporosis aim mainly at the prevention of fractures and bone loss in order to sustain patients quality of life. Even though there are plenty of different pharmaceutical options in the treatment and prophylaxis of tumour-therapy-induced osteoporosis, no other medication shows better or even similar results to bis phosphonates. There are numerous studies on different bisphosphonates (Clo, Pam, Ale, Ris, Iba, Zol) that investigated the effectiveness of those substances in prevention and treatment of TTI-osteoporosis in patients with breast and prostate cancer. All substances were supposed to increase the bone density as a main therapy goal and all substances reached that. Denosumab brings results which are at least of the same quality as bisphosphonates, when applied to patients with breast cancer, whose osteopenia was triggered by the usage of aromatase-inhibitors. Almost all women who received this antibody experienced an increase in bone density. But since the studies had a fairly low number of patients, it was impossible to recognize a difference in the occurrence rate of fractures, in contrast to patients with prostate cancer and androgen-blockade. Few discussions of the last years were as controverse as the one about whether osteoprotective substances could be used as an option to prevent from bone metastases. Part of the reason is, that the results of all studies were quite divergent especially those that investigated the usage of Clodronate and Zoledronate as an adjuvant drug. But in a recent meta-analysis of studies it was clearly shown, that bisphosphonates increase the bone-metastases-free and the total survival rate of postmenopausal breast cancer patients significantly, despite the fact that the way of application, patients collective and criterias of participation differed vastly, throughout the investigated studies. So there are plenty of reasons to study the indication further and to find out which patients have an advantage of an adjuvant usage and which does not. According to our current knowledge, those patients are the ones with a high risk of a relapse, an activated bonemetabolism and/or tumour cells in the bone marrow.

Schlüsselwörter

Knochenmetastasen - RANK/RANKL/OPGSignalweg - Bisphosphonate - Denosumab

Keywords

Bone metastases - RANK/RANKL/OPG signal path - bisphosphonates - denosumab
 

  • Literatur

  • 1 Solomayer EF, Diel IJ, Meyberg GC. et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000; 59: 271-278.
    CrossrefPubMedGoogle Scholar
  • 2 Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nature Rev 2002; 02: 563-572.
    Google Scholar
  • 3 Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev 2002; 02: 584-593.
    Google Scholar
  • 4 Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
    CrossrefPubMedGoogle Scholar
  • 5 Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19: 3562-3571.
    CrossrefPubMedGoogle Scholar
  • 6 Rodan GA, Fleisch H. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692-2696.
    CrossrefPubMedGoogle Scholar
  • 7 Rogers MJ, Frith JC, Luckman SP. et al. Molecular mechanism of action of bisphosphonates. Bone 1999; 24: 73S-79S.
    CrossrefPubMedGoogle Scholar
  • 8 Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer 2000; 01: 43-51.
    CrossrefPubMedGoogle Scholar
  • 9 Paterson AHG, Powles TJ, Kanis JA. et al. Doubleblind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
    CrossrefPubMedGoogle Scholar
  • 10 Hortobagyi GN, Theriault RL, Porter L. et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-1791.
    CrossrefPubMedGoogle Scholar
  • 11 Hortobagyi GN, Theriault RL, Lipton A. et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16: 2038-2044.
    CrossrefPubMedGoogle Scholar
  • 12 Body JJ, Diel IJ, Lichinitser MR. et al. Intravenous Ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-1405.
    CrossrefPubMedGoogle Scholar
  • 13 Body JJ, Diel IJ, Lichinitser M. et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with with metastatic bone disease; results from two randomized, placebocontrolled phase III studies. Br J Cancer 2004; 90: 1133-1137.
    CrossrefPubMedGoogle Scholar
  • 14 Diel IJ, Body JJ, Lichinitser MR. et al. Improved quality of life for long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004; 40: 1704-1712.
    CrossrefPubMedGoogle Scholar
  • 15 Rosen LS, Gordon D, Kaminski M. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind comparative trial. Cancer J 2001; 07: 377-387.
    Google Scholar
  • 16 Rosen LS, Gordon DH, Dugan W. et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100: 36-43.
    CrossrefPubMedGoogle Scholar
  • 17 Van Poznak CH, Temin GC, Yee GC. et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221-1227.
    CrossrefPubMedGoogle Scholar
  • 18 Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
    CrossrefPubMedGoogle Scholar
  • 19 Lacey DL, Timms E, Tan HL. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
    CrossrefPubMedGoogle Scholar
  • 20 Hofbauer LC, Heufelder AE. Role of receptor activator of nuklear factor-kappa B ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243-253.
    CrossrefPubMedGoogle Scholar
  • 21 Body JJ, Facon T, Coleman RE. et al. A study of the biological receptor activator of nuklear factorkappa B ligand inhibitor, denusomab in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228.
    CrossrefPubMedGoogle Scholar
  • 22 Stopeck AT, Lipton A, Body JJ. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized double-blind 3 study. J Clin Oncol 2010; 35: 5132-5139.
    Google Scholar
  • 23 Fizazi K, Carducci M, Smith M. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised double-blind study. Lancet 2011; 377: 813-822.
    CrossrefPubMedGoogle Scholar
  • 24 Henry DH, Costa L, Goldwasser F. et al. Randomized double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
    CrossrefPubMedGoogle Scholar
  • 25 Lipton A, Fizazi K, Stopeck AT. et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082-3092.
    CrossrefPubMedGoogle Scholar
  • 26 Cleeland CS, Body JJ. Stopeck et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, doubleblind study of denosumab and zoledronic acid. Cancer 2013; 119: 832-838.
    CrossrefPubMedGoogle Scholar
  • 27 Martin M, Bell R, Bourgeois H. et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 2012; 18: 4841-4849.
    CrossrefPubMedGoogle Scholar
  • 28 Vadhan-Raj S, von Moos R, Fallowfield LJ. et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012; 23: 3045-3051.
    CrossrefPubMedGoogle Scholar
  • 29 Diel IJ, Body JJ, Stopeck AT. et al. The role of denosumab in the prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease (submitted). And poster presentation at EMCC 2011. Abstract 3051.
    Google Scholar
  • 30 Stopeck AT, Fizazi K, Body JJ. et al. Safety of long term denosumab therapy: Results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer (accepted for publication). Poster presentation at SABCS 2011. Abstract P3–16–07.
    Google Scholar
  • 31 Saad F, Brown JE, Van Poznak C. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded activecontrolled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-1347.
    CrossrefPubMedGoogle Scholar
  • 32 Body JJ, Lipton A, Henry DH. et al. Hypocalcemia in patients with metastatic bone disease receiving denosumab. J Clin Oncol. 2013 31. (Suppl): Abstract 9628..
    PubMedGoogle Scholar
  • 33 Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment; pathophysiology and management. J Clin Oncol 2000; 18: 1570-1593.
    CrossrefPubMedGoogle Scholar
  • 34 Cummings SR, Browner WS, Bauer D. et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998; 339: 733-738.
    CrossrefPubMedGoogle Scholar
  • 35 Kanis J, McCloskey EV, Powles T. et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999; 79: 1179-1181.
    CrossrefPubMedGoogle Scholar
  • 36 Chen Z, Maricic M, Bassford TL. et al. Fracture risk among breast cancer survivors. Results from the women`s health initiative observational study. Arch Intern Med 2005; 165: 552-558.
    CrossrefPubMedGoogle Scholar
  • 37 Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19: 3306-3311.
    CrossrefPubMedGoogle Scholar
  • 38 Sverrisdottir A, Fornander T, Jacobsson H. et al. Bone mineral density among premenopausal woman with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2005; 22: 3694-3699.
    Google Scholar
  • 39 Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006; 24: 5305-5312.
    CrossrefPubMedGoogle Scholar
  • 40 Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G. et al. Zoledronic acid prevents cancer treatmentinduced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormoneresponsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820-828.
    CrossrefPubMedGoogle Scholar
  • 41 Gnant M, Mlineritsch B, Luschin-Ebengreuth G. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early breast cancer: 5-year follow-up of the ABCSG-12 bonemineral density substudy. Lancet Oncol 2008; 09: 840-849.
    CrossrefPubMedGoogle Scholar
  • 42 Brufsky A, Harker WG, Beck JT. et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25: 829-836.
    CrossrefPubMedGoogle Scholar
  • 43 Brufsky A, Bundred N, Coleman R. et al. Integrated analysis of zoledronic acid for prevention of araomatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. The Oncologist 2008; 13: 503-514.
    CrossrefPubMedGoogle Scholar
  • 44 Powles TJ, McCloskey E, Paterson AH. et al. Oral clodronate and reduction in loss of bone mineral density in women with operable breast cancer. J Natl Cancer Inst 1998; 90: 704-708.
    CrossrefPubMedGoogle Scholar
  • 45 Delmas PD, Balena R, Confravreux E. et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebocontrolled study. J Clin Oncol 1997; 15: 955-962.
    CrossrefPubMedGoogle Scholar
  • 46 Van Poznak C, Hannon RA, Mackey JR. et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28 (06) 967-975.
    CrossrefPubMedGoogle Scholar
  • 47 Lester JE, Dodwell DE, Purohit OP. et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336-6342.
    CrossrefPubMedGoogle Scholar
  • 48 Ellis G, Bone HG, Chlebowski R. et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875-4882.
    CrossrefPubMedGoogle Scholar
  • 49 Smith MR, Egerdie B, Hernándes NToriz. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755.
    CrossrefPubMedGoogle Scholar
  • 50 Diel IJ, Solomayer EF, Costa SD. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-363.
    CrossrefPubMedGoogle Scholar
  • 51 Diel IJ. Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol 2001; 28: 75-80.
    CrossrefPubMedGoogle Scholar
  • 52 Diel IJ, Jaschke A, Solomayer EF. et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrowA long-term follow-up Ann Oncol. 2008; 19: 2007-2011.
    PubMedGoogle Scholar
  • 53 Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19: 10-11.
    CrossrefPubMedGoogle Scholar
  • 54 Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in nodepositive breast cancer patients. Acta Oncol 2004; 43: 650-656.
    CrossrefPubMedGoogle Scholar
  • 55 Powles TJ, Paterson AHG, Kanis JA. et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-3224.
    CrossrefPubMedGoogle Scholar
  • 56 Powles T, Paterson A, McCloskey E. et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 08: R13.
    CrossrefPubMedGoogle Scholar
  • 57 Paterson AHG, Anderson SJ, Lembersky BC. et al. Oral clodronate for adjuvant treatment of operable breast cancer (NSABP-project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012; 13: 734-742.
    CrossrefPubMedGoogle Scholar
  • 58 Gnant M, Mlineritsch B, Schippinger W. et al. Endocrine therapy plus zoledronic acid in premenopausal brast cancer. New Engl J Med 2009; 360: 679-691.
    CrossrefPubMedGoogle Scholar
  • 59 Gnant M, Mlineritsch B, Stoeger H. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12: 631-641.
    CrossrefPubMedGoogle Scholar
  • 60 Eidtmann H, de Boer R, Bundred N. et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-months results of the ZO-FAST-study. Ann Oncol 2010; 21: 2188-2194.
    CrossrefPubMedGoogle Scholar
  • 61 Coleman R, de Boer R, Eidtmann H. et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398-405.
    CrossrefPubMedGoogle Scholar
  • 62 Coleman RE, Marshall H, Cameron D. et al. Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-1405.
    CrossrefPubMedGoogle Scholar
  • 63 Von Minckwitz G, Moebus V, Schneeweiss A. et al. German Adjuvant Intergroup Node-positive Study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31: 3531-3539.
    CrossrefPubMedGoogle Scholar
  • 64 Winter MC, Coleman RE. Bisphosphonates in the adjuvant treatment of breast cancer: an overview. Clin Oncol 2013; 25: 135-145.
    CrossrefPubMedGoogle Scholar
  • 65 He M, Fan W, Zhang X. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis. J Hematol Oncol. 2013 06. 80 http://www.jhoonline org/content/6/1/80.
    Google Scholar
  • 66 Yan T, Yin W, Zhou Q. et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials. Eur J Cancer 2012; 48: 187-195.
    PubMedGoogle Scholar
  • 67 Valachis A, Polyzos NP, Coleman RE. et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 2013; 18: 353-361.
    CrossrefPubMedGoogle Scholar
  • 68 Figueroa-Magalhães Miller RS. Bone-Modifying Agents as Adjuvant Therapy for early-stage breast cancer. Oncology. 2012 26. 955-962 http://www.http://www.cancernetwork.com/breast-cancer/ content/article/10165/2107660
    PubMedGoogle Scholar
  • 69 Zhu J, Zheng Y, Zhou Z. Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: Results from an updated systematic review and meta-analysis. Eur J Cancer 2013; 49: 2086-2092.
    CrossrefPubMedGoogle Scholar
  • 70 Coleman R, Gnant M, Paterson A. et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer. A meta-analysis of individual patients data from randomized trials. SABCS 2013, abstract S4–S7.
    Google Scholar